SCHEMBL1462575

SCHEMBL1462575

N#CN1CCN(c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.51
MAPT P10636 3/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 2/20 0.48
CHRNA7 P36544 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
HTR3E A5X5Y0 1/20 0.48
HTR3B O95264 1/20 0.48
ADRB1 P08588 1/20 0.48
HTR3A P46098 1/20 0.48
HTR3D Q70Z44 1/20 0.48
HTR3C Q8WXA8 1/20 0.48
DRD4 P21917 1/20 0.47
KCNH2 Q12809 1/20 0.47
HTT P42858 1/20 0.46
KCNA3 P22001 1/20 0.46
DRD2 P14416 2/20 0.46
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
CHRNB2 P17787 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16924853 0.81 LMNA (0.67) MAPTLMNACHRNA7SIGMAR1HTR3E
SCHEMBL576454 0.81 LMNA (0.67) MAPTLMNACHRNA7SIGMAR1HTR3E
SCHEMBL385012 0.81
SCHEMBL164538 0.81 LMNA (0.67) MAPTLMNACHRNA7SIGMAR1HTR3E
SCHEMBL576814 0.81 LMNA (0.67) MAPTLMNACHRNA7SIGMAR1HTR3E
SCHEMBL10552158 0.79 MAPT (0.52) MAPTKDM4ELMNADRD4DRD2
SCHEMBL3076371 0.78 DRD4 (0.52) MAPTKDM4ELMNACHRNA7SIGMAR1
SCHEMBL6650835 0.78 LMNA (0.48) MAPTKDM4ELMNACHRNA7SIGMAR1
SCHEMBL7258870 0.78 LMNA (0.64) MAPTLMNACHRNA7SIGMAR1HTR3E
SCHEMBL1280470 0.77 KDM4E (0.56) USP30MAPTKDM4ELMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3277676-B1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS PF MEDICAMENT (FR) 2023-03-22 EP disclosed
CN-111265525-A Treatment of hepatitis delta virus infection 艾格尔峰生物制药有限公司 2020-06-12 CN disclosed
CN-106535895-B Treatment of hepatitis delta virus infection 艾格尔峰生物制药有限公司 2020-02-28 CN disclosed
US-10450299-B2 Substituted quinazoline derivatives as DNA methyltransferase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2019-10-22 US disclosed
US-10450299-B2 Substituted quinazoline derivatives as DNA methyltransferase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2019-10-22 US disclosed
CN-104211708-B Benzoxazinone derivatives and its application as antiseptic 中国医学科学院药物研究所 2018-08-24 CN disclosed
US-20180118717-A1 Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2018-05-03 US disclosed
US-20180118717-A1 Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2018-05-03 US disclosed
US-20180118717-A1 Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2018-05-03 US disclosed
EP-3277676-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS Pierre Fabre Médicament (FR) 2018-02-07 EP disclosed
EP-1622894-B1 ANTITUMORAL ANTIANDROGENIC PYRROLIDINES BAYER SCHERING PHARMA AG (DE) 2009-01-14 EP disclosed
WO-2008044033-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2008-04-17 WO disclosed
US-20070021481-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-25 US disclosed
US-7138421-B2 Anti-androgenic pyrrolidines with tumor-inhibiting action SCHRING AKTIENGESELLSCHAFT (DE) 2006-11-21 US disclosed
EP-1622894-A1 ANTITUMORAL ANTIADROGENIC PYRROLIDINES Schering Aktiengesellschaft (DE) 2006-02-08 EP disclosed
US-20050159468-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-21 US disclosed
US-6861432-B2 Piperazine derivatives that destabilize androgen receptors SCHERING AKTIENGESELLSCHAFT (DE) 2005-03-01 US disclosed
WO-2004099188-A1 ANTITUMORAL ANTIADROGENIC PYRROLIDINES SCHERING AKTIENGESELLSCHAFT (DE) 2004-11-18 WO disclosed
US-20040009969-A1 Piperazine derivatives that destabilize androgen receptors SCHERING AG (DE) 2004-01-15 US disclosed
WO-2003043983-A1 PIPERAZINE DERIVATIVES DESTABILISING ANDROGEN RECEPTORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021481-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action NR5A1, AR, CYP17A1 USP30 4349/4885MAPT 4842/4885KDM4E 2146/4885
US-10450299-B2 Substituted quinazoline derivatives as DNA methyltransferase inhibitors DNMT1, DNMT3A, DNMT3B USP30 2692/4885MAPT 1559/4885KDM4E 205/4885
US-20050159468-A1 Anti-androgenic pyrrolidines with tumor-inhibiting action NR5A1, AR, CYP17A1 USP30 4349/4885MAPT 4842/4885KDM4E 2146/4885
US-20040009969-A1 Piperazine derivatives that destabilize androgen receptors AR, FSHR, GNRHR USP30 2316/4885MAPT 4808/4885KDM4E 1947/4885
US-20180118717-A1 Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors DNMT1, DNMT3A, DNMT3B USP30 2692/4885MAPT 1559/4885KDM4E 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.